RNA-binding proteins regulating the CD44 alternative splicing.
| Autor: | Maltseva D; Faculty of Biology and Biotechnology, HSE University, Moscow, Russia., Tonevitsky A; Faculty of Biology and Biotechnology, HSE University, Moscow, Russia.; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in molecular biosciences [Front Mol Biosci] 2023 Dec 01; Vol. 10, pp. 1326148. Date of Electronic Publication: 2023 Dec 01 (Print Publication: 2023). |
| DOI: | 10.3389/fmolb.2023.1326148 |
| Abstrakt: | Alternative splicing is often deregulated in cancer, and cancer-specific isoform switches are part of the oncogenic transformation of cells. Accumulating evidence indicates that isoforms of the multifunctional cell-surface glycoprotein CD44 play different roles in cancer cells as compared to normal cells. In particular, the shift of CD44 isoforms is required for epithelial to mesenchymal transition (EMT) and is crucial for the maintenance of pluripotency in normal human cells and the acquisition of cancer stem cells phenotype for malignant cells. The growing and seemingly promising use of splicing inhibitors for treating cancer and other pathologies gives hope for the prospect of using such an approach to regulate CD44 alternative splicing. This review integrates current knowledge about regulating CD44 alternative splicing by RNA-binding proteins. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Maltseva and Tonevitsky.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|